Tags : Reyvow


Eli Lilly Launches Reyvow (lasmiditan) C-V for the Treatment of

Shots: Eli Lilly launches Reyvow C-V 50/100/200mg, indicated for the acute treatment of migraine with/without aura & will be available in US pharmacies in the next few days The efficacy of the therapy is evaluated in SAMURAI and SPARTAN studies assessing Reyvow vs PBO in 4439 patients with migraine, results demonstrated that patients achieved fast […]Read More